Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE N/A. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $42M | $708M | $205M | $206M | $184M | $846M | $662M | $856M | — | — | — |
| Enterprise Value | $206M | $873M | $361M | $386M | $297M | $848M | $360M | $760M | — | — | — |
| P/E Ratio → | -0.24 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.86 | 14.62 | 1.78 | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 6.94 | 3.28 | 15.20 | 6.97 | 2.07 | 2.43 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 18.00 | 3.15 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 97.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -336.8% | -336.8% | -52.2% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -351.5% | -351.5% | -49.3% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -122.5% | -480.5% | -343.5% | -105.8% | -72.3% | -155.6% | — | — | — |
| ROA | -69.9% | -69.9% | -18.0% | -61.5% | -74.5% | -53.0% | -50.4% | -54.3% | -122.5% | -2681.6% | -138.3% |
| ROIC | -107.5% | -107.5% | -20.9% | -74.7% | -131.6% | -228.9% | -114.7% | -880.2% | — | — | — |
| ROCE | -86.1% | -86.1% | -22.6% | -76.0% | -83.0% | -53.7% | -47.3% | -61.2% | -136.6% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 6.88 | 3.38 | 18.69 | 1.53 | 0.57 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 5.32 | 2.87 | 9.42 | 0.02 | -0.94 | -0.27 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -1.00 |
| Interest Coverage | -14.86 | -14.86 | -3.83 | -12.31 | -15.53 | -11.04 | -18.21 | — | -12246.42 | -56.38 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.64 | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
| Quick Ratio | 2.64 | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
| Cash Ratio | 2.16 | 2.16 | 6.54 | 5.74 | 5.19 | 8.16 | 13.26 | 10.88 | 11.21 | 0.25 | 0.42 |
| Asset Turnover | — | 0.28 | 0.36 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 94.33 | 16.99 | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $229M | $226M | $226M | $85M | $75M | $69M | $55M | $60M | $25M | $9M |
Clinical trial funding shortfall
As reported in financial statements, GOSS trades at a price-to-sales ratio of 0.76, which, when viewed alongside a forward EV/EBITDA of 34.56, suggests that the market is pricing the company based on speculative future milestone success rather than current operational performance or tangible asset value.
The valuation multiples appear disconnected from traditional fundamental metrics due to the absence of recurring revenue. Investors should monitor whether the current P/S ratio adequately accounts for the high probability of future equity dilution required to fund the ongoing PROSERA trial.
Based on reported figures, the company's ROIC has trended deeply into negative territory, reaching -160.6% in 2026Q1, which indicates that the firm is currently consuming capital at an unsustainable rate relative to the progress of its clinical development pipeline.
The sharp decline in return on invested capital highlights the inefficiency of historical R&D spending on discontinued programs. This trend suggests that management must demonstrate a significant improvement in capital allocation efficiency to justify further investment in the seralutinib asset.
According to recent SEC filings, the company's asset turnover ratio remains extremely low at 0.11, reflecting a business model that is heavily weighted toward non-productive clinical assets rather than revenue-generating operations that would typically drive higher turnover in a commercial-stage biotechnology firm.
The lack of meaningful asset turnover confirms that the company's balance sheet is dominated by cash and R&D-related intangibles rather than operational infrastructure. The high DSO figures, while volatile, suggest that the timing of collaboration payments remains the primary driver of working capital fluctuations.
As indicated by the current ratio of 2.20 in 2026Q1, the company maintains a superficial appearance of liquidity, yet this is undermined by a high quarterly burn rate that threatens to exhaust cash reserves before the next major clinical data readout occurs.
The quick ratio, which mirrors the current ratio, confirms that the company lacks inventory or other liquid assets to support operations, leaving it entirely dependent on cash on hand. This liquidity profile warrants further investigation into the firm's ability to secure non-dilutive financing in the near term.
The price-to-sales ratio is the most commonly misapplied metric for GOSS, as it obscures the fact that the company's revenue is derived from non-recurring milestone payments rather than sustainable product sales, rendering traditional valuation comparisons to commercial-stage peers fundamentally flawed and potentially misleading.
Investors should instead focus on the cash runway and the net cash used in operating activities to assess the company's true financial viability. Relying on P/S multiples in a pre-commercial biotech context ignores the reality that revenue is a byproduct of partnership accounting rather than market demand.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GOSS stock.
Gossamer Bio, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Based on historical data, Gossamer Bio, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Gossamer Bio, Inc. has 97.9% gross margin and -336.8% operating margin.